Table 2.
Nature of exchanged sera and kit usage
| Serum | Source1 | HLA antibody specificities | Kit2 | |||||
|---|---|---|---|---|---|---|---|---|
| Class I | Class II | Scr | PRAI | PRAII | SAI | SAII | ||
| 1 | EU | B44,B45,B76,B82 | DR7,DR53,DQ2 | X3 | x | x | x | x |
| 2 | EU | Bw4,A23,A24,A25,A32 | DR1,DR4,DR9,DR10,DR15,DR51,DR53,DR103,DQ5,DP1,DP3,DP5,DP9,DP11,DP14,DP17,DP19 | x | x | x | x | x |
| 3 | EU | A1,A3,A11,A23,A24,A36,A80,B37,B38,B39,B67,B76 | DR7,DR8,DR9,DR11,DR12,DR13,DR14,DR17,DR18,DR52,DQ4,DQ7, DQ8,DQ9 | x | x | x | x | x |
| 4 | EU | A66,B7,B13,B27,B39,B42,B47,B48,B54,B55,B56,B60,B61,B67,B73,B81, B82 | DR15,DR51,DQ5,DQ6 | x | x | x | x | x |
| 5 | EU | A1,A23,A24,A25,A32,A36,A43,A80,Bw4,B45,B62,B72,B76,B82 | DR4,DP1,DP2,DP4,DP5,DP11,DP13, DP19 | x | x | x | x | x |
| 6 | EU | Bw6,A1,A3,A11,A23,A24,A29,A36,A43,A80,B59 | DR1,DR4,DR9,DR15,DR16,DR51,DR103 | x | x | x | x | x |
| 7 | EU | A2,A3,A11,A23,A24,A32,A43,A68,A69,Bw4,B35,B4005,B41,B46,B47, B50,B56,B60,B61,B62,B72,B75,B78 | DR4,DP3,DP9,DP14,DP17 | x | x | x | x | x |
| 8 | EU | A2,A68,A69,A80,B57,B58 | DR103,DR11,DR12,DR13,DR16,DQ4,DQ5,DQ6,DQ8,DQ9,DP2,DP3,DP4,DP9,DP10,DP14,DP17 | x | x | x | x | x |
| 9 | EU | A23,A24,A25,A32,A66,B35,B38,B4005,B46,B48,B49,B51,B52,B53,B54,B56,B57,B58,B59,B62,B63,B71,B72,B75,B77,B78,Cw10 | DR7,DR9,DR12,DR52,DR53,DQ2,DQ4,DQ7,DQ9,DP1,DP3,DP4,DP5,DP10,DP11,DP13,DP14,DP17,DP18, DP19 | x | x | x | x | x |
| 10 | UCLA | B7,B8,B13,B18,B27,B35,B39,B41,B42,B45,B47,B48,B50,B54,B55,B56, B60,B61,B62,B64,B65,B67,B71,B72,B73,B75,B76,B78,B81,B82 | - | x | x | x | ||
| 11 | UCLA | B7,B27,B42,B48,B54,B55,B56,B60, B67,B81,B82 | - | x | x | x | ||
| 12 | UCLA | A23,A24,B13,B35,B38,B44,B45,B46,B49,B50,B51,B52,B53,B56,B57,B58,B62,B63,B71,B72,B75,B76,B77,B78 | - | x | x | x | ||
| 13 | UCLA | A1,A11,A25,A26,A29,A30,A31,A33,A34,A36,A43,A66,A68,A69,A80,B8,B38,B39,B41,B42,B54,B55,B57,B58,B59,B63,B67,B73,Cw6,Cw7,Cw18 | - | x | x | x | ||
| 14 | UCLA | - | DR15,DR16,DR51,DQ4,DQ5,DQ6 | x | x | x | ||
| 15 | UCLA | - | DR7,DR9,DQ2 | x | x | x | ||
| 16 | UCLA | - | DR51,DR7,DR9,DR10,DR15,DR16, DR53,DR103,DR1 | x | x | x | ||
| 17 | UCLA | - | DR11,DR13,DR14,DR17,DR18,DR52,DQ2,DQ7 | x | x | x | ||
| 18 | UCLA | - | DR4,DR53,DQ2,DQ4,DQ7,DQ8,DQ9 | x | x | x | ||
| 19 | UCLA | - | DR4,DR53,DQ8,DQ9 | x | x | x | ||
| 20 | UCLA | - | - | x | x | x | x | x |
1
Source: EU = Emory University, Atlanta; UCLA = University of California, Los Angeles.
2
Kit: Scr = screen; PRAI = panel reactive antibody class I; PRAII = panel reactive antibody class II; SAI = single antigen class I; SA2 = single antigen class II.
3
x: indicates serum was included in kit’s test set.